Recordati Industria Chimica e Farmaceutica S.p.A. (RCDTF)
| Previous close | 36.00 |
| Open | 36.00 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 36.00 - 36.00 |
| 52-week range | 36.00 - 63.96 |
| Volume | |
| Avg. volume | 5 |
| Market cap | 7.411B |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | 17.59 |
| EPS (TTM) | 2.05 |
| Earnings date | N/A |
| Forward dividend & yield | 1.22 (2.75%) |
| Ex-dividend date | 23 May 2022 |
| 1y target est | N/A |
- Business Wire
Recordati Rare Diseases Announce Publication of Long-term Outcomes From the Extension to the Phase III LINC 3 Study of Isturisa® (Osilodrostat) in Patients With Cushing’s Disease in the European Journal of Endocrinology
PUTEAUX, France, August 31, 2022--Recordati Rare Diseases announce today publication of the long-term outcomes from the open-label extension period of the Phase III LINC 3 study of Isturisa® in The European Journal of Endocrinology.1 These data support the long-term utility of Isturisa® in the maintenance treatment of patients with Cushing’s disease and reinforce Isturisa as an effective and well-tolerated oral therapy. Isturisa® is indicated in the EU for the treatment of adult patients with en
- Reuters
Recordati confirms 2022 targets despite Ukraine conflict
The Milan-based company, which operates in both Russia and Ukraine, said in a statement "the first quarter of 2022 was characterised by a general recovery in relevant markets" and that results were in line with the guidance set for the year. Earnings before interests, taxes, depreciation and amortization (EBITDA) in the months to March were up 8.7% 163.0 million euros ($171.77 million), lifted by a 9% increase in net revenue.
- Business Wire
Recordati Rare Diseases Announce Publication in the Journal of Clinical Endocrinology & Metabolism of the Phase III LINC 4 Study Confirming the Efficacy and Safety of Isturisa® (Osilodrostat) in Patients With Cushing’s Disease
PUTEAUX, France, March 29, 2022--Recordati Rare Diseases announce today the publication of positive results from the Phase III LINC 4 study of Isturisa in The Journal of Clinical Endocrinology & Metabolism.1 These data reinforce Isturisa as an effective and well-tolerated oral therapy for patients with Cushing’s disease. Isturisa is indicated in the EU for the treatment of adult patients with endogenous Cushing’s syndrome,2 a rare and debilitating condition of hypercortisolism that is most commo
